ROC-101 for hereditary sensory and autonomic neuropathies

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 16 Sep 2025: Trial registered, NCT07175038
  2. 1 Oct 2025: Trial started, NCT07175038

The trials

NCT07175038: A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)

State
Under way
Phase
Phase 2
People
40 planned
Started
1 Oct 2025
Primary completion
Mar 2027
Arms
ROC-101 Oral Dose
Results
None posted
  1. 16 Sep 2025: Trial registered
  2. 1 Oct 2025: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.